Definium Therapeutics prices $805M public offering of 20.6M shares at $34 each, upsized from $700M

Definium Therapeutics, Inc.

Offering of 20,588,236 common shares at $34.00 per share, with full exercise of underwriters' 30-day option for additional 3,088,235 shares.
Gross proceeds ~$805M; net proceeds ~$758M after underwriting discounts and expenses.
Proceeds to fund R&D, commercialization preparation for DT120 ODT if approved, and working capital.
Underwriters: J.P. Morgan, Jefferies, Leerink, BofA, Evercore ISI, Stifel, Oppenheimer, LifeSci.
Expected close June 25, 2026; 60-day lock-up for directors, officers, and company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.